Hormuzd A Katki

List of Publications by Year
in descending order

120 papers	6,832 citations	93792 39 h-index	73587 79 g-index
122 all docs	122 docs citations	122 times ranked	8702 citing authors

#	Article	IF	Citations
1	Efficient and robust propensityâ€scoreâ€based methods for population inference using epidemiologic cohorts. International Statistical Review, 2022, 90, 146-164.	1.1	6
2	A Quantitative Framework to Study Potential Benefits and Harms of Multi-Cancer Early Detection Testing. Cancer Epidemiology Biomarkers and Prevention, 2022, 31, 38-44.	1.1	8
3	Management of Lung Cancer Screening Results Based on Individual Prediction of Current and Future Lung Cancer Risks. Journal of Thoracic Oncology, 2022, 17, 252-263.	0.5	11
4	Inaccuracies in electronic health records smoking data and a potential approach to address resulting underestimation in determining lung cancer screening eligibility. Journal of the American Medical Informatics Association: JAMIA, 2022, 29, 779-788.	2.2	26
5	Abstract PR-13: Potential effect on racial/ethnic disparities of removing racial/ethnic variables from risk models: The example of lung-cancer screening. Cancer Epidemiology Biomarkers and Prevention, 2022, 31, PR-13-PR-13.	1.1	1
6	Inflammatory markers in women with reported benign gynecologic pathology: an analysis of the prostate, lung, colorectal and ovarian cancer screening trial.. Annals of Epidemiology, 2022, 68, 1-8.	0.9	1
7	Association of Antiparietal Cell and Anti-Intrinsic Factor Antibodies With Risk of Gastric Cancer. JAMA Oncology, 2022, 8, 268.	3.4	13
8	Body mass index and risk of progression from monoclonal gammopathy of undetermined significance to multiple myeloma: Results from the Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial. Blood Cancer Journal, 2022, 12, 51.	2.8	2
9	Using Prediction Models to Reduce Persistent Racial and Ethnic Disparities in the Draft 2020 USPSTF Lung Cancer Screening Guidelines. Journal of the National Cancer Institute, 2021, 113, 1590-1594.	3.0	77
10	Gastroesophageal reflux disease: A risk factor for laryngeal squamous cell carcinoma and esophageal squamous cell carcinoma in the NIHâ€AARP Diet and Health Study cohort. Cancer, 2021, 127, 1871-1879.	2.0	17
11	Risk-Based Selection of Individuals for Oral Cancer Screening. Journal of Clinical Oncology, 2021, 39, 663-674.	0.8	24
12	A simple framework to identify optimal costâ€effective risk thresholds for a single screen: Comparison to Decision Curve Analysis. Journal of the Royal Statistical Society Series A: Statistics in Society, 2021, 184, 887.	0.6	3
13	Aspirin, ibuprofen, and reduced risk of advanced colorectal adenoma incidence and recurrence and colorectal cancer in the PLCO Cancer Screening Trial. Cancer, 2021, 127, 3145-3155.	2.0	15
14	DNA-methylation-based telomere length estimator: comparisons with measurements from flow FISH and qPCR. Aging, 2021, 13, 14675-14686.	1.4	11
15	Prognostic impact of pre-transplant chromosomal aberrations in peripheral blood of patients undergoing unrelated donor hematopoietic cell transplant for acute myeloid leukemia. Scientific Reports, 2021, 11, 15004.	1.6	4
16	Screening for Lung Cancer. Chest, 2021, 160, e427-e494.	0.4	114
17	Population Attributable Risks of Subtypes of Esophageal and Gastric Cancers in the United States. American Journal of Gastroenterology, 2021, 116, 1844-1852.	0.2	24
18	Pre-HCT mosaicism increases relapse risk and lowers survival in acute lymphoblastic leukemia patients postâ€“unrelated HCT. Blood Advances, 2021, 5, 66-70.	2.5	6

#	Article	IF	Citations
19	The Improving Risk Informed HPV Screening (IRIS) Study: Design and Baseline Characteristics. Cancer Epidemiology Biomarkers and Prevention, 2021, , cebp.0865.2021.	1.1	3
20	Predicting Lung Cancer Occurrence in Never-Smoking Females in Asia: TNSF-SQ, a Prediction Model. Cancer Epidemiology Biomarkers and Prevention, 2020, 29, 452-459.	1.1	31
21	Absolute risks of cervical precancer among women who fulfill exiting guidelines based on HPV and cytology cotesting. International Journal of Cancer, 2020, 146, 617-626.	2.3	5
22	Basing Eligibility for Lung Cancer Screening on Individualized Risk Calculators Should Save More Lives, but Life Expectancy Matters. Journal of the National Cancer Institute, 2020, 112, 429-430.	3.0	10
23	Preâ€transplant short telomeres are associated with high mortality risk after unrelated donor haematopoietic cell transplant for severe aplastic anaemia. British Journal of Haematology, 2020, 188, 309-316.	1.2	9
24	Ischaemic heart disease and stroke mortality by specific coal type among non-smoking women with substantial indoor air pollution exposure in China. International Journal of Epidemiology, 2020, 49, 56-68.	0.9	20
25	Serum ghrelin and esophageal and gastric cancer in two cohorts in China. International Journal of Cancer, 2020, 146, 2728-2735.	2.3	21
26	Oral Leukoplakia and Risk of Progression to Oral Cancer: A Population-Based Cohort Study. Journal of the National Cancer Institute, 2020, 112, 1047-1054.	3.0	88
27	A Prospective Study of Circulating Chemokines and Angiogenesis Markers and Risk of Multiple Myeloma and Its Precursor. JNCI Cancer Spectrum, 2020, 4, pkz104.	1.4	10
28	Addressing Disparities in Lung Cancer Screening Eligibility and Healthcare Access. An Official American Thoracic Society Statement. American Journal of Respiratory and Critical Care Medicine, 2020, 202, e95-e112.	2.5	127
29	Number needed to test: quantifying risk stratification provided by diagnostic tests and risk predictions. Biostatistics and Epidemiology, 2020, , 1-15.	0.4	0
30	Response to Brandt, Bednarz-Knoll, Kleinheinz et al. Journal of the National Cancer Institute, 2020, 112, 970-971.	3.0	0
31	Statistical approaches using longitudinal biomarkers for disease early detection: A comparison of methodologies. Statistics in Medicine, 2020, 39, 4405-4420.	0.8	4
32	Association of donor IFNL4 genotype and non-relapse mortality after unrelated donor myeloablative haematopoietic stem-cell transplantation for acute leukaemia: a retrospective cohort study. Lancet Haematology,the, 2020, 7, e715-e723.	2.2	8
33	Improving external validity of epidemiologic cohort analyses: a kernel weighting approach. Journal of the Royal Statistical Society Series A: Statistics in Society, 2020, 183, 1293-1311.	0.6	15
34	Sampleâ€weighted semiparametric estimation of causeâ€specific cumulative risk and incidence using leftâ€• or intervalâ€censored data from electronic health records. Statistics in Medicine, 2020, 39, 2387-2402.	0.8	0
35	Risk Estimates Supporting the 2019 ASCCP Risk-Based Management Consensus Guidelines. Journal of Lower Genital Tract Disease, 2020, 24, 132-143.	0.9	116
36	Risk of Prostate Cancerâ€“related Death Following a Low PSA Level in the PLCO Trial. Cancer Prevention Research, 2020, 13, 367-376.	0.7	3

#	Article	IF	Citations
37	â€œI'm not a freshiâ€: Culture shock, puberty and growing up as British-Bangladeshi girls. Social Science and Medicine, 2020, 258, 113058.	1.8	7
38	Assessing Endogenous and Exogenous Hormone Exposures and Breast Development in a Migrant Study of Bangladeshi and British Girls. International Journal of Environmental Research and Public Health, 2020, 17, 1185.	1.2	4
39	2019 ASCCP Risk-Based Management Consensus Guidelines. Journal of Lower Genital Tract Disease, 2020, 24, 90-101.	0.9	66
40	Development and validation of an individualized risk prediction model for oropharynx cancer in the US population. Cancer, 2019, 125, 4407-4416.	2.0	19
41	Insights for Management of Ground-Glass Opacities From the National Lung Screening Trial. Journal of Thoracic Oncology, 2019, 14, 1662-1665.	0.5	17
42	Quantifying risk stratification provided by diagnostic tests and risk predictions: Comparison to AUC and decision curve analysis. Statistics in Medicine, 2019, 38, 2943-2955.	0.8	9
43	Prioritized concordance index for hierarchical survival outcomes. Statistics in Medicine, 2019, 38, 2868-2882.	0.8	7
44	A Pragmatic Testing-Eligibility Framework for Population Mutation Screening: The Example of BRCA1/2. Cancer Epidemiology Biomarkers and Prevention, 2019, 28, 293-302.	1.1	6
45	Circulating inflammation markers and colorectal adenoma risk. Carcinogenesis, 2019, 40, 765-770.	1.3	14
46	Contemporary Implications of U.S. Preventive Services Task Force and Risk-Based Guidelines for Lung Cancer Screening Eligibility in the United States. Annals of Internal Medicine, 2019, 171, 384.	2.0	18
47	Life-Gainedâ€“Based Versus Risk-Based Selection of Smokers for Lung Cancer Screening. Annals of Internal Medicine, 2019, 171, 623.	2.0	72
48	Role of Screening History in Clinical Meaning and Optimal Management of Positive Cervical Screening Results. Journal of the National Cancer Institute, 2019, 111, 820-827.	3.0	20
49	Testing Positive on a Multigene Panel Does Not Suffice to Determine Disease Risks. Journal of the National Cancer Institute, 2018, 110, 797-798.	3.0	4
50	A novel metric that quantifies risk stratification for evaluating diagnostic tests: The example of evaluating cervical-cancer screening tests across populations. Preventive Medicine, 2018, 110, 100-105.	1.6	9
51	Donor telomere length and causes of death after unrelated hematopoietic cell transplantation in patients with marrow failure. Blood, 2018, 131, 2393-2398.	0.6	15
52	Clinical Outcomes after Conservative Management of Cervical Intraepithelial Neoplasia Grade 2 (CIN2) in Women Ages 21â€“39 Years. Cancer Prevention Research, 2018, 11, 165-170.	0.7	26
53	Relative Performance of HPV and Cytology Components of Cotesting in Cervical Screening. Journal of the National Cancer Institute, 2018, 110, 501-508.	3.0	116
54	Challenges in risk estimation using routinely collected clinical data: The example of estimating cervical cancer risks from electronic health-records. Preventive Medicine, 2018, 111, 429-435.	1.6	15

#	Article	IF	Citations
55	Nonparametric Adjustment for Measurement Error in Time-to-Event Data: Application to Risk Prediction Models. Journal of the American Statistical Association, 2018, 113, 14-25.	1.8	4
56	Is the Womenâ€™s Health Initiative (WHI) Dietary Modification Associated With a Reduced Risk of Pancreatic Cancer?. Journal of the National Cancer Institute, 2018, 110, 9-10.	3.0	1
57	Epidemiologic Evidence That Excess Body Weight Increases Risk of Cervical Cancer by Decreased Detection of Precancer. Journal of Clinical Oncology, 2018, 36, 1184-1191.	0.8	65
58	Preventing Lung Cancer Mortality by Computed Tomography Screening: The Effect of Risk-Based Versus U.S. Preventive Services Task Force Eligibility Criteria, 2005â€“2015. Annals of Internal Medicine, 2018, 168, 229.	2.0	42
59	Effect of Several Negative Rounds of Human Papillomavirus and Cytology Co-testing on Safety Against Cervical Cancer. Annals of Internal Medicine, 2018, 168, 20.	2.0	50
60	Implications of Nine Risk Prediction Models for Selecting Ever-Smokers for Computed Tomography Lung Cancer Screening. Annals of Internal Medicine, 2018, 169, 10.	2.0	130
61	Sleep Duration across the Adult Lifecourse and Risk of Lung Cancer Mortality: A Cohort Study in Xuanwei, China. Cancer Prevention Research, 2017, 10, 327-336.	0.7	11
62	Kinetics of the Human Papillomavirus Type 16 E6 Antibody Response Prior to Oropharyngeal Cancer. Journal of the National Cancer Institute, 2017, 109, .	3.0	77
63	Flexible risk prediction models for left or interval-censored data from electronic health records. Annals of Applied Statistics, 2017, 11, 1063-1084.	0.5	15
64	Potential Impact of Including Time to First Cigarette in Risk Models for Selecting Ever-Smokers for Lung Cancer Screening. Journal of Thoracic Oncology, 2017, 12, 1646-1653.	0.5	12
65	Mixture models for undiagnosed prevalent disease and interval-censored incident disease: applications to a cohort assembled from electronic health records. Statistics in Medicine, 2017, 36, 3583-3595.	0.8	25
66	Proof-of-principle study of a novel cervical screening and triage strategy: Computer-analyzed cytology to decide which HPV-positive women are likely to have â‰¥CIN2. International Journal of Cancer, 2017, 140, 718-725.	2.3	19
67	Response to Safiri etÂal. â€œComments on Potential Impact of Including Time to First Cigarette in Risk Models for Selecting Ever-Smokers for Lung Cancer Screeningâ€• Journal of Thoracic Oncology, 2017, 12, e208.	0.5	1
68	Applying Risk Prediction Models to Optimize Lung Cancer Screening: Current Knowledge, Challenges, and Future Directions. Current Epidemiology Reports, 2017, 4, 307-320.	1.1	13
69	0303â€…Evaluating differences in expert agreement between subgroups to identify where to prioritise use of multiple raters. , 2017, , .		0
70	Correlation of Leukocyte Telomere Length Measurement Methods in Patients with Dyskeratosis Congenita and in Their Unaffected Relatives. International Journal of Molecular Sciences, 2017, 18, 1765.	1.8	42
71	Associations between self-reported diabetes and 78 circulating markers of inflammation, immunity, and metabolism among adults in the United States. PLoS ONE, 2017, 12, e0182359.	1.1	7
72	Reply to Letter: Using novel risk stratification statistics to better understand the value of screening tests. International Journal of Cancer, 2016, 139, 1669-1669.	2.3	0

#	Article	IF	Citations
73	Development and Validation of Risk Models to Select Ever-Smokers for CT Lung Cancer Screening. JAMA - Journal of the American Medical Association, 2016, 315, 2300.	3.8	248
74	Effect of Recipient Age and Stem Cell Source on the Association between Donor Telomere Length and Survival after Allogeneic Unrelated Hematopoietic Cell Transplantation for Severe Aplastic Anemia. Biology of Blood and Marrow Transplantation, 2016, 22, 2276-2282.	2.0	22
75	Burden of HPV-positive oropharynx cancers among ever and never smokers in the U.S. population. Oral Oncology, 2016, 60, 61-67.	0.8	75
76	A risk-based framework to decide who benefits from screening. Nature Reviews Clinical Oncology, 2016, 13, 531-532.	12.5	11
77	Risk assessment to guide cervical screening strategies in a large <scp>C</scp>hinese population. International Journal of Cancer, 2016, 138, 2639-2647.	2.3	16
78	Cancer risk among the HIV-infected elderly in the United States. Aids, 2016, 30, 1663-1668.	1.0	55
79	Risk Stratification Using Human Papillomavirus Testing among Women with Equivocally Abnormal Cytology: Results from a State-Wide Surveillance Program. Cancer Epidemiology Biomarkers and Prevention, 2016, 25, 36-42.	1.1	14
80	Associations of Coffee Drinking with Systemic Immune and Inflammatory Markers. Cancer Epidemiology Biomarkers and Prevention, 2015, 24, 1052-1060.	1.1	59
81	A study of HPV typing for the management of HPV-positive ASC-US cervical cytologic results. Gynecologic Oncology, 2015, 138, 573-578.	0.6	49
82	Leukoplakia, Oral Cavity Cancer Risk, and Cancer Survival in the U.S. Elderly. Cancer Prevention Research, 2015, 8, 857-863.	0.7	33
83	Rationale and design of a long term follow-up study of women who did and did not receive HPV 16/18 vaccination in Guanacaste, Costa Rica. Vaccine, 2015, 33, 2141-2151.	1.7	17
84	Circulating Inflammation Markers, Risk of Lung Cancer, and Utility for Risk Stratification. Journal of the National Cancer Institute, 2015, 107, .	3.0	77
85	Cigarette Smoking and Variations in Systemic Immune and Inflammation Markers. Journal of the National Cancer Institute, 2014, 106, .	3.0	255
86	A migrant study of pubertal timing and tempo in British-Bangladeshi girls at varying risk for breast cancer. Breast Cancer Research, 2014, 16, 469.	2.2	19
87	Reassurance Against Future Risk of Precancer and Cancer Conferred by a Negative Human Papillomavirus Test. Journal of the National Cancer Institute, 2014, 106, dju153-dju153.	3.0	200
88	Response. Journal of the National Cancer Institute, 2014, 107, dju390-dju390.	3.0	0
89	Tracking and Evaluating Molecular Tumor Markers With Cancer Registry Data: HER2 and Breast Cancer. Journal of the National Cancer Institute, 2014, 106, .	3.0	30
90	GBV-C Infection and Risk of NHL among U.S. Adults. Cancer Research, 2014, 74, 5553-5560.	0.4	48

#	Article	IF	Citations
91	Tumor-Based Caseâ€“Control Studies of Infection and Cancer: Muddling the When and Where of Molecular Epidemiology. Cancer Epidemiology Biomarkers and Prevention, 2014, 23, 1959-1964.	1.1	3
92	Body Mass Index, Physical Activity, and Serum Markers of Inflammation, Immunity, and Insulin Resistance. Cancer Epidemiology Biomarkers and Prevention, 2014, 23, 2840-2849.	1.1	79
93	Childhood Environment Influences Adrenarcheal Timing among First-Generation Bangladeshi Migrant Girls to the UK. PLoS ONE, 2014, 9, e109200.	1.1	26
94	Targeting of Low-Dose CT Screening According to the Risk of Lung-Cancer Death. New England Journal of Medicine, 2013, 369, 245-254.	13.9	492
95	Circulating Inflammation Markers and Prospective Risk for Lung Cancer. Journal of the National Cancer Institute, 2013, 105, 1871-1880.	3.0	198
96	Selection Criteria for Lung-Cancer Screening. New England Journal of Medicine, 2013, 368, 728-736.	13.9	740
97	Benchmarking CIN 3+ Risk as the Basis for Incorporating HPV and Pap Cotesting into Cervical Screening and Management Guidelines. Journal of Lower Genital Tract Disease, 2013, 17, S28-S35.	0.9	167
98	Five-Year Risks of CIN 2+ and CIN 3+ Among Women With HPV-Positive and HPV-Negative LSIL Pap Results. Journal of Lower Genital Tract Disease, 2013, 17, S43-S49.	0.9	49
99	Five-Year Risks of CIN 3+ and Cervical Cancer Among WomenWho Test Pap-Negative But Are HPV-Positive. Journal of Lower Genital Tract Disease, 2013, 17, S56-S63.	0.9	73
100	Five-Year Risk of Recurrence After Treatment of CIN 2, CIN 3, or AIS. Journal of Lower Genital Tract Disease, 2013, 17, S78-S84.	0.9	75
101	Follow-up Testing After Colposcopy. Journal of Lower Genital Tract Disease, 2013, 17, S69-S77.	0.9	59
102	Five-Year Risk of CIN 3+ to Guide the Management of Women Aged 21 to 24 Years. Journal of Lower Genital Tract Disease, 2013, 17, S64-S68.	0.9	28
103	Five-Year Risks of CIN 3+ and Cervical Cancer Among Women With HPV Testing of ASC-US Pap Results. Journal of Lower Genital Tract Disease, 2013, 17, S36-S42.	0.9	85
104	Five-Year Risks of CIN 3+ and Cervical Cancer Among Women With HPV-Positive and HPV-Negative High-Grade Pap Results. Journal of Lower Genital Tract Disease, 2013, 17, S50-S55.	0.9	59
105	2012 Updated Consensus Guidelines for the Management of Abnormal Cervical Cancer Screening Tests and Cancer Precursors. Obstetrics and Gynecology, 2013, 121, 829-846.	1.2	617
106	How might HPV testing be integrated into cervical screening?. Lancet Oncology, The, 2012, 13, 8-10.	5.1	15
107	Estimating the agreement and diagnostic accuracy of two diagnostic tests when one test is conducted on only a subsample of specimens. Statistics in Medicine, 2012, 31, 436-448.	0.8	23
108	Cervical cancer risk for women undergoing concurrent testing for human papillomavirus and cervical cytology: a population-based study in routine clinical practice. Lancet Oncology, The, 2011, 12, 663-672.	5.1	504

#	Article	IF	Citations
109	Effectiveness of VIA, Pap, and HPV DNA Testing in a Cervical Cancer Screening Program in a Peri-Urban Community in Andhra Pradesh, India. PLoS ONE, 2010, 5, e13711.	1.1	100
110	Using DNA Fingerprints to Infer Familial Relationships Within NHANES III Households. Journal of the American Statistical Association, 2010, 105, 552-563.	1.8	9
111	Risk estimation for the next generation of prevention programmes for cervical cancer. Lancet Oncology, The, 2009, 10, 1022-1023.	5.1	44
112	Multiple diseases in carrier probability estimation: Accounting for surviving all cancers other than breast and ovary in BRCAPRO. Statistics in Medicine, 2008, 27, 4532-4548.	0.8	16
113	Hematologic and Biochemical Changes Associated with Human T Lymphotropic Virus Type 1 Infection in Jamaica: A Report from the Population-Based Blood Donors Study. Clinical Infectious Diseases, 2007, 45, 975-982.	2.9	8
114	Breast-cancer risk in BRCA -mutation-negative women from BRCA -mutation-positive families. Lancet Oncology, The, 2007, 8, 1042-1043.	5.1	13
115	Incorporating medical interventions into carrier probability estimation for genetic counseling. BMC Medical Genetics, 2007, 8, 13.	2.1	18
116	Specifying and Implementing Nonparametric and Semiparametric Survival Estimators in Two-Stage (Nested) Cohort Studies With Missing Case Data. Journal of the American Statistical Association, 2006, 101, 460-471.	1.8	28
117	Effect of Misreported Family History on Mendelian Mutation Prediction Models. Biometrics, 2006, 62, 478-487.	0.8	16
118	Assessing uncertainty in reference intervals via tolerance intervals: application to a mixed model describing HIV infection. Statistics in Medicine, 2005, 24, 3185-3198.	0.8	15
119	Influence function based variance estimation and missing data issues in case-cohort studies. , 2001, 7, 331-344.		17
120	Prospective Study of Serum Selenium Levels and Incident Esophageal and Gastric Cancers. Journal of the National Cancer Institute, 2000, 92, 1753-1763.	3.0	230